EH301 for the Treatment of Amyotrophic Lateral Sclerosis: a Placebo-Controlled Study

Trial Profile

EH301 for the Treatment of Amyotrophic Lateral Sclerosis: a Placebo-Controlled Study

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2018

At a glance

  • Drugs Nicotinamide-riboside/pterostilbene (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Elysium Health
  • Most Recent Events

    • 06 Apr 2018 New trial record
    • 29 Mar 2018 According to the Elysium Health media release, company plans to initiate this trial by the fourth quarter of 2018 in collaboration with Mayo Clinic.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top